Biohaven BHVN Stock
Biohaven Price Chart
Biohaven BHVN Financial and Trading Overview
| Biohaven stock price | 13.9 USD |
| Previous Close | 15.61 USD |
| Open | 15.97 USD |
| Bid | 0 USD x 30000 |
| Ask | 15.97 USD x 30000 |
| Day's Range | 15.12 - 16.15 USD |
| 52 Week Range | 7.48 - 18.24 USD |
| Volume | 1.67M USD |
| Avg. Volume | 3.18M USD |
| Market Cap | 2.3B USD |
| Beta (5Y Monthly) | 3.135 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.77 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.73 USD |
BHVN Valuation Measures
| Enterprise Value | 2.44B USD |
| Trailing P/E | N/A |
| Forward P/E | -8.168516 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -5.107 |
Trading Information
Biohaven Stock Price History
| Beta (5Y Monthly) | 3.135 |
| 52-Week Change | 78.66% |
| S&P500 52-Week Change | 14.40% |
| 52 Week High | 18.24 USD |
| 52 Week Low | 7.48 USD |
| 50-Day Moving Average | 13.71 USD |
| 200-Day Moving Average | 12.27 USD |
BHVN Share Statistics
| Avg. Volume (3 month) | 3.18M USD |
| Avg. Daily Volume (10-Days) | 5.54M USD |
| Shares Outstanding | 151.06M |
| Float | 116.59M |
| Short Ratio | 7.2 |
| % Held by Insiders | 11.20% |
| % Held by Institutions | 96.09% |
| Shares Short | 17.9M |
| Short % of Float | 15.16% |
| Short % of Shares Outstanding | 11.84% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | September 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -90.56% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -478048096 USD |
| Net Income Avi to Common (ttm) | -542676992 USD |
| Diluted EPS (ttm) | -3.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 161.12M USD |
| Total Cash Per Share (mrq) | 1.07 USD |
| Total Debt (mrq) | 300.44M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.051 |
| Book Value Per Share (mrq) | -0.65 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -472529984 USD |
| Levered Free Cash Flow (ttm) | -229341808 USD |
Profile of Biohaven
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 215 Church Street |
| ZIP | 06510 |
| Phone | 203 404 0410 |
| Website | https://www.biohaven.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 274 |
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Q&A For Biohaven Stock
What is a current BHVN stock price?
Biohaven BHVN stock price today per share is 13.9 USD.
How to purchase Biohaven stock?
You can buy BHVN shares on the NYSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biohaven?
The stock symbol or ticker of Biohaven is BHVN.
Which industry does the Biohaven company belong to?
The Biohaven industry is Biotechnology.
How many shares does Biohaven have in circulation?
The max supply of Biohaven shares is 151.06M.
What is Biohaven Price to Earnings Ratio (PE Ratio)?
Biohaven PE Ratio is now.
What was Biohaven earnings per share over the trailing 12 months (TTM)?
Biohaven EPS is -3.77 USD over the trailing 12 months.
Which sector does the Biohaven company belong to?
The Biohaven sector is Healthcare.
Biohaven BHVN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
|
- | |||||
US Tech US 700 Small Cap Index
NQUS700SC
US
|
2969.71 USD — |
-4.27
|
— — | 2981.75 USD — | 3100.49 USD — | — - | — — |
|
NYSE Composite Index
NYA
US
|
23955.98 USD — |
-2.96
|
— — | — — | — — | — - | — — |
